MAP4K4 Antibody
-
中文名稱：MAP4K4兔多克隆抗體
-
貨號：CSB-PA781476
-
規格：￥2024
-
圖片：
-
Western blot analysis of extracts from COLO cells and HUVEC cells, using MEKKK 4 antibody. -
Immunofluorescence analysis of A549 cells, using MEKKK 4 antibody.
-
-
其他：
產品詳情
-
產品名稱：Rabbit anti-Homo sapiens (Human) MAP4K4 Polyclonal antibody
-
Uniprot No.：
-
基因名：
-
宿主：Rabbit
-
反應種屬：Human,Mouse
-
免疫原：Synthesized peptide derived from internal of Human MEKKK 4.
-
免疫原種屬：Homo sapiens (Human)
-
克隆類型：Polyclonal
-
純化方式：The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
-
濃度：It differs from different batches. Please contact us to confirm it.
-
產品提供形式：Liquid
-
應用范圍：ELISA,WB,IF
-
推薦稀釋比：
Application Recommended Dilution WB 1:500-1:3000 IF 1:100-1:500 -
Protocols：
-
儲存條件：Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期：Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
-
用途：For Research Use Only. Not for use in diagnostic or therapeutic procedures.
產品評價
相關產品
靶點詳情
-
功能：Serine/threonine kinase that may play a role in the response to environmental stress and cytokines such as TNF-alpha. Appears to act upstream of the JUN N-terminal pathway. Phosphorylates SMAD1 on Thr-322.
-
基因功能參考文獻：
- an anti-cancer effect of microRNA-141 on breast cancer by cytotoxic CD4+ T cells through MAP4K4 expression. PMID: 29620289
- the close proximity between AcSDKP and FGFR1 was essential for the suppression of TGFbeta/smad signaling and EndMT associated with MAP4K4 phosphorylation (P-MAP4K4) in endothelial cells. PMID: 28771231
- RBM4-SRSF3-MAP4K4 constitutes a novel mechanism for manipulating the metastasis of colorectal cancer cells through the JNK1 signaling pathway. PMID: 29138007
- these findings identify MAP4K4 as a novel MAPK/ERK pathway regulator in lung adenocarcinoma that is required for lung adenocarcinoma maintenance. PMID: 28306189
- This report identifies HGK methylation/downregulation in T cells as a potential biomarker for non-obese type 2 diabetes PMID: 26918832
- Results reveal that endothelial Map4k4 is critical for lymphatic vascular development by regulating endothelial cells (EC)quiescence and lymphatic EC fate. PMID: 27044870
- of the five variants, SNP rs2236935T/C was significantly associated with type 2 diabetes mellitus (T2DM) in this study population; conclude that MAP4K4 gene is associated with T2DM in a Chinese Han population, and MAP4K4 gene variants may contribute to the risk toward the development of T2DM PMID: 27174326
- Interactions between MAP4K4 gene variants and environmental factors may contribute to MAP4K4 attenuation in T cells, leading to non-obese T2D. PMID: 28061846
- MAP4K4 promotes the epithelial-mesenchymal transition and invasiveness of hepatocellular carcinoma cells PMID: 27010469
- miR-194 regulated the progression of hepatocellular carcinoma through directly inhibiting the expression of MAP4K4 PMID: 26722431
- The results of the present study suggested that inhibition of MAP4K4 may be a therapeutic strategy for gastric cancer. PMID: 26549737
- loss of MAP4K4 function suppressed pathological angiogenesis in disease models, identifying MAP4K4 as a potential therapeutic target PMID: 25799996
- that MAP4K4, a known mediator of inflammation, is involved in KS aetiology by regulating KSHV lytic reactivation PMID: 24244164
- results reveal a key target of SOX2 expression and highlight the unexpected context-dependent role for MAP4K4, a pluripotent activator of several mitogen-activated protein kinase pathways, in regulating tumor cell survival. PMID: 24233838
- TRAF1.NIK is a central complex linking canonical and non-canonical pathways by disrupting the TRAF2-cIAP2 ubiquitin ligase complex PMID: 23543740
- Common polymorphisms in MAP4K4 are associated with insulin resistance and beta-cell dysfunction, possibly via this gene's role in inflammatory signaling. PMID: 23094072
- Elevated MAP4K4 expression is closely associated with lung adenocarcinoma progression with independent prognostic value in predicting overall survival for patients with lung adenocarcinoma. PMID: 22824148
- MAP4K4 overexpression is an independent predictor of poor prognosis of Hepatocellular Carcinoma patients, and inhibition of its expression might be of therapeutic significance PMID: 21196414
- Data show that down-regulation of hepatocyte progenitor kinase-like kinase (HGK) can obviously inhibit the migration and invasion of HepG2 cells in vitro, and suggest that HGK may be a new therapeutic target for treatment of hepatocellular carcinoma. PMID: 20857524
- interaction with GBP3 PMID: 12387898
- The STE20 kinase HGK is broadly expressed in human tumor cells and can modulate cellular transformation, invasion, and adhesion. PMID: 12612079
- MAP4K4 is a putative effector of Rap2, a Ras family small GTP-binding protein, mediating the activation of JNK by Rap2 PMID: 14966141
- studies of the promigratory role of MAP4K4 showed that the knockdown of this transcript inhibited the migration of multiple carcinoma cell lines, indicating a broad role in cell motility PMID: 16537454
- MAP4K4 silencing prevents TNFa-induced insulin resistance in human skeletal muscle and restores appropriate signaling inputs to enhance glucose uptake PMID: 17227768
- MAP4K4 expression significantly correlated with overall and recurrence-free survival (P=0.025 and 0.004) independent of age, tumor size, differentiation, and stage. PMID: 18981001
顯示更多
收起更多
-
亞細胞定位：Cytoplasm.
-
蛋白家族：Protein kinase superfamily, STE Ser/Thr protein kinase family, STE20 subfamily
-
組織特異性：Widely expressed. Isoform 5 is abundant in the brain. Isoform 4 is predominant in the liver, skeletal muscle and placenta.
-
數據庫鏈接：
Most popular with customers
-
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-
